Qube Research & Technologies (QRT)
ACAD icon

Qube Research & Technologies (QRT)’s Acadia Pharmaceuticals ACAD Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.9M Buy
2,446,610
+1,496,311
+157% +$32.9M 0.06% 428
2026
Q1 		$21.2M Sell
950,299
-252,302
-21% -$6.03M 0.02% 855
2025
Q4 		$32.1M Buy
1,202,601
+606,159
+102% +$14.5M 0.03% 685
2025
Q3 		$12.7M Sell
596,442
-187,404
-24% -$4.43M 0.01% 1169
2025
Q2 		$16.9M Buy
783,846
+134,636
+21% +$2.5M 0.02% 972
2025
Q1 		$10.8M Buy
649,210
+17,788
+3% +$323K 0.01% 1083
2024
Q4 		$11.6M Buy
631,422
+212,019
+51% +$3.42M 0.02% 1012
2024
Q3 		$6.45M Sell
419,403
-685,703
-62% -$11.4M 0.01% 1267
2024
Q2 		$18M Buy
1,105,106
+461,036
+72% +$7.44M 0.03% 644
2024
Q1 		$11.9M Buy
644,070
+363,811
+130% +$9.01M 0.02% 773
2023
Q4 		$8.77M Buy
280,259
+67,340
+32% +$1.61M 0.02% 784
2023
Q3 		$4.44M Buy
212,919
+188,080
+757% +$5.11M 0.01% 989
2023
Q2 		$595K Buy
+24,839
New +$552K ﹤0.01% 1474
2023
Q1 		– Sell
-30,721
Closed -$489K – 2484
2022
Q4 		$489K Buy
+30,721
New +$480K ﹤0.01% 1481
2022
Q2 		– Sell
-12,825
Closed -$311K – 2432
2022
Q1 		$311K Buy
+12,825
New +$310K ﹤0.01% 1770
2021
Q1 		– Sell
-48,226
Closed -$2.58M – 1863
2020
Q4 		$2.58M Buy
+48,226
New +$2.39M 0.04% 521
2020
Q3 		– Sell
-161,431
Closed -$7.83M – 1614
2020
Q2 		$7.83M Buy
+161,431
New +$7.75M 0.11% 219
2020
Q1 		– Sell
-5,940
Closed -$254K – 1073
2019
Q4 		$254K Buy
+5,940
New +$258K 0.01% 1299

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ACAD Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Acadia Pharmaceuticals (ACAD) stake by 157% in Q2 2026, buying an estimated $32.9M and bringing the position to 2,446,610 shares worth $61.9M. The position accounts for 0.06% of the portfolio, ranked #428.

Qube Research & Technologies (QRT) first reported a position in ACAD in Q4 2019 and has held it in 18 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Qube Research & Technologies (QRT) held 2,446,610 shares of Acadia Pharmaceuticals worth $61.9M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 1,496,311 Acadia Pharmaceuticals shares in Q2 2026, an estimated $32.9M.
  • Acadia Pharmaceuticals made up 0.06% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #428 holding.
  • Qube Research & Technologies (QRT) first reported a position in Acadia Pharmaceuticals in Q4 2019 and has held it in 18 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.